Treatment of Excessive Bleeding in Jehovah's Witness Patients after Cardiac Surgery with Recombinant Factor VIIa (NovoSeven®)

Tanaka, Kenichi A.; Waly, Amr A.; Cooper, William A.; Levy, Jerrold H.

doi:10.1097/00000542-200306000-00034

Cited by 98 publications

(49 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it has been successfully utilized to promote hemostasis in intractable hemorrhage [2]. Our patient's successful outcome supports the few previous findings [2][3][4][5] …”

Section: Sacha Zeerledersupporting

confidence: 86%

Comment on hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit by Okabayashi et al.

Voves¹,

Wuillemin²

2005

Am. J. Hematol.

View full text Add to dashboard Cite

“…Moreover, it has been successfully utilized to promote hemostasis in intractable hemorrhage [2]. Our patient's successful outcome supports the few previous findings [2][3][4][5] …”

Section: Sacha Zeerledersupporting

confidence: 86%

Comment on hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit by Okabayashi et al.

Voves¹,

Wuillemin²

2005

Am. J. Hematol.

View full text Add to dashboard Cite

“…Moreover, it has been successfully utilized to promote hemostasis in intractable hemorrhage [2]. Our patient's successful outcome supports the few previous findings [2][3][4][5] that rFVIIa may represent an effective therapeutic option, which does not contrast with their beliefs, for the management of severe hemorrhage in Jehovah's Witnesses.…”

Section: Successful Treatment Of Intestinal Hemorrhage In a Jehovah'ssupporting

confidence: 81%

Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient

Veneri

Franchini

2005

Am. J. Hematol.

View full text Add to dashboard Cite

“…78 In anecdotal reports, administration of 1 to 2 doses of rfVIIa at 90 to 120 g per kg/BW has resulted in effective hemostasis, again without evidence of systemic activation of the clotting system. 79 Despite reports of the successful use of rfVIIa, there are reports suggesting that it is not always effective. 80 FVIIa has been used to arrest bleeding in children with large and disfiguring facial hemangiomas.…”

Section: Use Of Factor Viia In Surgerymentioning

confidence: 99%

The use of recombinant factor VIIa in the treatment of bleeding disorders

Roberts

Monroe

White

2004

Blood

248

207

View full text Add to dashboard Cite

Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been used "off-label" to enhance hemostasis in nonhemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophilic patients with inhibitors is both safe and effective. Anecdotal reports also suggest that the product is safe and effective in controlling bleeding in nonhemophilic patients. However, its use in these conditions has not been approved by the FDA, and conclusive evidence of its effectiveness from controlled clinical trials is not yet available. Several questions pertaining to the use of factor VIIa require further investigation, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; and laboratory tests for monitoring therapy. (Blood.

show abstract

Treatment of Excessive Bleeding in Jehovah's Witness Patients after Cardiac Surgery with Recombinant Factor VIIa (NovoSeven®)

Cited by 98 publications

References 16 publications

Comment on hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit by Okabayashi et al.

Comment on hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit by Okabayashi et al.

Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient

The use of recombinant factor VIIa in the treatment of bleeding disorders

Contact Info

Product

Resources

About